Aljundi, W.; Daas, L.; Suffo, S.; Seitz, B.; Abdin, A.D.
First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. Pharmaceutics 2024, 16, 470.
https://doi.org/10.3390/pharmaceutics16040470
AMA Style
Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD.
First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. Pharmaceutics. 2024; 16(4):470.
https://doi.org/10.3390/pharmaceutics16040470
Chicago/Turabian Style
Aljundi, Wissam, Loay Daas, Shady Suffo, Berthold Seitz, and Alaa Din Abdin.
2024. "First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration" Pharmaceutics 16, no. 4: 470.
https://doi.org/10.3390/pharmaceutics16040470
APA Style
Aljundi, W., Daas, L., Suffo, S., Seitz, B., & Abdin, A. D.
(2024). First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. Pharmaceutics, 16(4), 470.
https://doi.org/10.3390/pharmaceutics16040470